| Literature DB >> 30083556 |
Moshe Bachar1, Eduard Fatakhov1, Christopher Banerjee1, Nathan Todnem1.
Abstract
Objectives. We describe a rare case of nonalcoholic Marchiafava-Bignami disease (MBD) in the setting of malnourishment after gastric bypass. Methods. A 44-year-old nonalcoholic Caucasian woman with malnutrition after gastric bypass presented with 2 weeks of weakness. The patient acutely became stuporous. Brain magnetic resonance imaging showed lesions in the corpus callosum and internal capsules consistent with MBD. After 10 days of treatment, the patient had resolution of her encephalopathy with return to baseline mental function, with radiological improvement. Results. MBD is a rare neurological disorder seen in alcoholics and can rapidly progress to coma or death. Our patient was successfully treated with a regimen typically used in alcoholics. We discuss the relevant literature supporting this regimen. Conclusions. This case demonstrates that since the pathophysiological etiology of the disease is malnutrition, MBD patients can be effectively treated with this regimen regardless of the underlying cause.Entities:
Keywords: Marchiafava-Bignami disease; gastric bypass; malnourishment
Year: 2018 PMID: 30083556 PMCID: PMC6062771 DOI: 10.1177/2324709618784318
Source DB: PubMed Journal: J Investig Med High Impact Case Rep ISSN: 2324-7096
Figure 1.Sagittal fluid attenuated inversion recovery image showing lesion (white arrow) in the splenium of the corpus callosum.
Figure 2.Axial diffusion weighted imaging showing lesions in the splenium (white arrow) and posterior limb of both internal capsules (black arrows). Below are the repeat axial diffusion weighted images obtained 15 days later showing resolution of splenium and internal capsule abnormalities.
An Outline of the Treatment Duration, Dosage, and Medication for Our Patient.
| Day | Thiamine | Pyridoxine (Vitamin B6) | Methylprednisolone | Cyanocobalamin (Vitamin B12) | Folic Acid |
|---|---|---|---|---|---|
| 1/8-14 | 100 mg PO q24h | 1 mg PO q24h | |||
| 1/15 | 100 mg in 50 mL NS IV ×1 and 100 mg PO q24h | 1 g IM ×1 | 1 mg PO q24h | ||
| 1/16 | 500 mg in 100 mL NS IV q8h and 100 mg PO q24h | 1 mg PO q24h | |||
| 1/17 | 500 mg in 100 mL NS IV q8h and 100 mg PO q24h | 1 g in 100 mL NS IV q24h | 1 g IM ×1 | 1 mg PO q24h | |
| 1/18 | 500 mg in 100 mL NS IV q24h | 1 g in 100 mL NS IV q24h | |||
| 1/19 | 500 mg in 100 mL NS IV q24h | 1 g in 100 mL NS IV q24h | |||
| 1/20 | 500 mg in 100 mL NS IV q24h | 1 g in 100 mL NS IV q24h | |||
| 1/21 | 500 mg in 100 mL NS IV q24h | 100 mg PO q24h | 1 g in 100 mL NS IV q24h | 1 mg PO q24h | |
| 1/22 | 500 mg in 100 mL NS IV q24h | 100 mg PO q24h | 1 mg PO q24h | ||
| 1/23 | 100 mg PO q24h | 1 mg PO q24h | |||
| 1/24 | 100 mg in 50 mL NS IV q24h | 100 mg PO q24h | 1 mg PO q24h | ||
| 1/25 | 100 mg in 50 mL NS IV q24h | 100 mg PO q24h | 1 mg PO q24h | ||
| 1/26 | 100 mg in 50 mL NS IV q24h | 1 mg PO q24h |
Abbreviations: NS, normal saline; IV, intravenous; IM, intramuscular.